Sun Pharmaceutical Industries has been granted a patent for a JAK1 and/or JAK2 inhibitor compound for treating hair loss disorders. The compound has a specific structural formula and can be used in pharmaceutical compositions with other therapeutic agents. GlobalData’s report on Sun Pharmaceutical Industries gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s company profile on Sun Pharmaceutical Industries, Nanoparticle drug conjugates was a key innovation area identified from patents. Sun Pharmaceutical Industries's grant share as of February 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

The granted patent (Publication Number: US11919907B2) discloses a compound represented by a specific structural formula, with various claims detailing the composition and methods of use. The compound can have deuterium incorporation at specific positions, with percentages specified in the claims. Additionally, the patent covers pharmaceutical compositions containing the compound, along with JAK inhibitors, in tablet or capsule form. Methods for inhibiting JAK activity in cells, treating diseases like hair loss disorders (such as alopecia areata), and administering JAK inhibitors to human subjects are also outlined in the claims.

Furthermore, the patent describes methods for treating diseases or disorders that benefit from JAK inhibition in human subjects by administering pharmaceutical compositions containing specific JAK inhibitors. The patent specifies the dosage of the inhibitors and the use of additional JAK inhibitors in combination. The use of a phosphate salt as a pharmaceutically acceptable salt in the compositions is also highlighted in the claims. Overall, the patent provides a comprehensive overview of the compound's structure, pharmaceutical compositions, and methods for inhibiting JAK activity and treating related diseases or disorders in human subjects, emphasizing the potential therapeutic applications of the disclosed compound and compositions.

To know more about GlobalData’s detailed insights on Sun Pharmaceutical Industries, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies